M
Maria Ornella Nicoletto
Publications - 55
Citations - 3005
Maria Ornella Nicoletto is an academic researcher. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 19, co-authored 53 publications receiving 2300 citations.
Papers
More filters
Journal ArticleDOI
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine,Jonathan A. Ledermann,Frédéric Selle,Val Gebski,Richard T Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Andres Poveda,Sandro Pignata,Michael Friedlander,Nicoletta Colombo,Philipp Harter,Keiichi Fujiwara,Isabelle Ray-Coquard,Susana Banerjee,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Patricia Pautier,Tomasz Byrski,Giovanni Scambia,Maria Ornella Nicoletto,Fiona Nussey,Andrew R Clamp,Richard T. Penson,Amit M. Oza,Andrés Poveda Velasco,Manuel Rodrigues,Jean-Pierre Lotz,Diane Provencher,Aleix Prat Aparicio,Laura Vidal Boixader,Clare L. Scott,Kenji Tamura,Mayu Yunokawa,Alla Lisyanskaya,Jacques Medioni,Nicolas Pécuchet,Coraline Dubot,Thibault De La Motte Rouge,Marie-Christine Kaminsky,Béatrice Weber,Alain Lortholary,Christine Parkinson,Jonathan A. Ledermann,Sarah Williams,Jonathan Cosin,James Hoffman,Marie Plante,Allan Covens,Gabe S. Sonke,Florence Joly,Anne Floquet,H. Hirte,Amnon Amit,Tjoung-Won Park-Simon,Koji Matsumoto,Sergei Tjulandin,Jae Hoon Kim,Jae Hoon Kim,Laurence Gladieff,Roberto Sabbatini,David M. O'Malley,Patrick Timmins,Daniel Kredentser,Nuria Laínez Milagro,Maria Pilar Barretina Ginesta,Ariadna Tibau Martorell,Alfonso Gómez de Liaño Lista,Belén Ojeda González,Linda Mileshkin,Masaki Mandai,Ingrid A. Boere,Petronella B. Ottevanger,Joo-Hyun Nam,Elias Abdo Filho,Salima Hamizi,Francesco Cognetti,David Warshal,Elizabeth Dickson-Michelson,Scott Kamelle,Nathalie McKenzie,Gustavo C. Rodriguez,Deborah K. Armstrong,Eva Chalas,Paul Celano,Kian Behbakht,Susan E Davidson,Stephen Welch,Limor Helpman,Ami Fishman,Ilan Bruchim,Magdalena Sikorska,Anna Słowińska,Wojciech Rogowski,Mariusz Bidziński,Beata Śpiewankiewicz,Antonio Casado Herraez,César Mendiola Fernández,Martina Gropp-Meier,Toshiaki Saito,Kazuhiro Takehara,Takayuki Enomoto,Hidemichi Watari,Chel Hun Choi,Byoung-Gie Kim,Jae Weon Kim,Jae Weon Kim,Roberto Hegg,Ignace Vergote +110 more
TL;DR: Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.
Journal ArticleDOI
Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation
Anna Pastò,Chiara Bellio,Giorgia Pilotto,Vincenzo Ciminale,Micol Silic-Benussi,Giulia Guzzo,Andrea Rasola,Chiara Frasson,Giorgia Nardo,Elisabetta Zulato,Maria Ornella Nicoletto,Mariangela Manicone,Stefano Indraccolo,Alberto Amadori +13 more
TL;DR: The metabolic profile of cancer stem cells isolated from patients with epithelial ovarian cancer showed higher mitochondrial reactive oxygen species (ROS) production and elevated membrane potential, and underwent apoptosis upon inhibition of the mitochondrial respiratory chain.
Journal ArticleDOI
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois,Gunnar B. Kristensen,Isabelle Ray-Coquard,Alexander Reuss,Sandro Pignata,Nicoletta Colombo,Nicoletta Colombo,Ursula Denison,Ignace Vergote,Jose Maria Del Campo,Petronella B. Ottevanger,Martin Heubner,Thomas Minarik,Emmanuel Sevin,Nikolaus de Gregorio,Mariusz Bidziński,Jacobus Pfisterer,Susanne Malander,Felix Hilpert,Mansoor Raza Mirza,Giovanni Scambia,Werner Meier,Maria Ornella Nicoletto,Line Bjørge,Alain Lortholary,Martin Oliver Sailer,Michael Merger,Philipp Harter +27 more
TL;DR: This double-blind phase 3 trial investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer and found progression-free survival was significantly longer in the nintEDanib group than in the placebo group.
Journal ArticleDOI
Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Catherine Lhommé,Florence Joly,Joan L. Walker,Andrea A. Lissoni,Maria Ornella Nicoletto,Gregory M. Manikhas,Mark M.O. Baekelandt,Alan N. Gordon,Paula M. Fracasso,William L. Mietlowski,Gary J. Jones,Margaret H. Dugan +11 more
TL;DR: The addition of valspodar to PC did not improve TTP or OS and was more toxic compared with PC in untreated patients with advanced ovarian or primary peritoneal cancer.
Journal ArticleDOI
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Michael Friedlander,Val Gebski,Emma Gibbs,Lucy Davies,Lucy Davies,Ralph Bloomfield,Felix Hilpert,Lari Wenzel,Daniel Eek,Manuel Rodrigues,Andrew R Clamp,Richard T. Penson,Diane Provencher,Jacob Korach,Tomasz Huzarski,Laura Vidal,Vanda Salutari,Clare L. Scott,Maria Ornella Nicoletto,Kenji Tamura,David Espinoza,Florence Joly,Eric Pujade-Lauraine +22 more
TL;DR: Olaparib maintenance therapy did not have a significant detrimental effect on HRQOL compared with placebo and patient-centred endpoints support the improvement in progression-free survival, the primary endpoint in SOLO2, and should be included in future trials of maintenance therapies.